IMR Press / CEOG / Volume 42 / Issue 4 / DOI: 10.12891/ceog1925.2015

Clinical and Experimental Obstetrics & Gynecology (CEOG) is published by IMR Press from Volume 47 Issue 1 (2020). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with S.O.G.

Case Report
Transient azoospermia following rosuvastatin medication for hypercholesterolemia
Show Less
1 IVF Center, Oak Clinic, Nishinari-ku, Osaka (Japan)
Clin. Exp. Obstet. Gynecol. 2015, 42(4), 545–546; https://doi.org/10.12891/ceog1925.2015
Published: 10 August 2015
Abstract

The authors report a case of transient azoospermia following hydroxymethylglutaryl-coenzyme A reductase (HMGCR) inhibitor rosuvastatin medication for hypercholesterolemia. While a primary infertile couple with oligoasthenospermia was preparing for an in vitro fertilization program, the male partner had been diagnosed with hypercholesterolemia in a medical check-up and prescribed fourweek oral administration of rosuvastatin. No motile spermatozoa were found in the ejaculated semen and urine on the day of follicular aspiration. Azoospermia was confirmed by re-examination in weeks 3 and 7. Spermatozoa appeared in the ejaculated semen in two weeks of drug withdrawal. In week 16, the sperm count and motility increased to the level where intracytoplasmic sperm injection was available.
Keywords
Azoospermia
Rosuvastatin
Hypercholesterolemia
In vitro fertilization
Share
Back to top